6,678 trials
Chronic Hepatitis C · Hemodialysis
Primary: 1.Number of Participants With Sustained Virologic Response (SVR) 2.Number of Participants Who Droppoed Out of the Study Prematurely Due to Adverse Events (AEs) — 13; 8…
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 12 Weeks — 0.081; -0.025 Liters — p=<0.0001
Spondylarthropathies, Enthesitis
Primary: Normalized Net Incremental Area Under the Curve (AUC) for Patient Global Assessment of Disease Activity (PGA) Between Randomization and Week 12 — -28.54; -11.07 mm…
Hypercholesterolemia
Primary: Number of Participants Reaching the LDL-C (Low Density Lipoprotein-Cholesterol) Goal (< 100 mg/dl) After 6 Weeks of Treatment — 89; 63 Participants
Dyslipidemia · Hypertension
Primary: Subjects With Blood Pressure (BP) <140/90 Millimeters of Mercury (mmHg) and Low Density Lipoprotein Cholesterol (LDL-C) <100 Milligrams Per Deciliter(mg/dL) at Week 6…
Type 2 Diabetes Mellitus
Primary: Median Change From Baseline in the Insulin Secretory Capacity After a 36-month Treatment — -3.9; -75.3; 7.0; 74.6 picomoles/L per minute (pmol/L*min) — p=0.376
Influenza
Primary: Percentage of Participants With Solicited Injection Site and Systemic Reactions Post-Vaccination With Fluzone® — 15; 7; 0; 2 Percentage of Participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 — -1.7; -1.4 percent
Hypercholesterolemia
Primary: Area Under the Curve From Predose (Time Zero) to 48 Hours Post-dose (AUC48) — 135.05; 140.79 ng.h/mL
Schizophrenia
Primary: Medication Satisfaction Questionnaire (MSQ) Score Change From Baseline to the Week 6 Endpoint. — 2.5; 2.3; 2.4 Points on a scale — p=<0.001
Hypercholesterolemia
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Infinity) — 168.1355; 176.1731 ng*hr/mL
Hypercholesterolemia
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Infinity) — 18.3206; 19.2583 ng•hr/mL
Infections, Fungal
Primary: Plasma Concentrations of Voriconazole — 839.50; 2182.33 ng/mL
Central Neuropathic Pain
Primary: Mean Pain Score at Endpoint as Measured by Daily Pain Rating Scale (DPRS) — 4.8; 5.0 scores on scale — p=0.578
Non-small Cell Lung Cancer
Primary: Proportion of Participants With a Complete or Partial Response (Objective Response Rate [ORR]) — 0.182 proportion of responders